AAAAAA

   
Results: 1-25 |
Results: 25
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma
Authors: Motzer, RJ Rakhit, A Thompson, JA Nemunaitis, J Murphy, BA Ellerhorst, J Schwartz, LH Berg, WJ Bukowski, RM
Citation: Rj. Motzer et al., Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma, J INTERF CY, 21(4), 2001, pp. 257-263
Tumor-induced sensitivity to apoptosis in T cells from patients with renalcell carcinoma: Role of nuclear factor-kappa B suppression
Authors: Finke, JH Rayman, P George, R Tannenbaum, CS Kolenko, V Uzzo, R Novick, AC Bukowski, RM
Citation: Jh. Finke et al., Tumor-induced sensitivity to apoptosis in T cells from patients with renalcell carcinoma: Role of nuclear factor-kappa B suppression, CLIN CANC R, 7(3), 2001, pp. 940S-946S
Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: Clinical and laboratory effects
Authors: Tate, J Olencki, T Finke, J Kottke-Marchant, K Rybicki, LA Bukowski, RM
Citation: J. Tate et al., Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: Clinical and laboratory effects, ANN ONCOL, 12(5), 2001, pp. 655-659
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma
Authors: Olencki, T Peereboom, D Wood, L Budd, GT Novick, A Finke, J McLain, D Elson, P Bukowski, RM
Citation: T. Olencki et al., Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma, J CANC RES, 127(5), 2001, pp. 319-324
Roles of NF-kappa B and 26 S proteasome in apoptotic cell death induced bytopoisomerase I and II poisons in human nonsmall cell lung carcinoma
Authors: Tabata, M Tabata, R Grabowski, DR Bukowski, RM Ganapathi, MK Ganapathi, R
Citation: M. Tabata et al., Roles of NF-kappa B and 26 S proteasome in apoptotic cell death induced bytopoisomerase I and II poisons in human nonsmall cell lung carcinoma, J BIOL CHEM, 276(11), 2001, pp. 8029-8036
Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependentenzymes
Authors: Aoyama, M Grabowski, DR Holmes, KA Rybicki, LA Bukowski, RM Ganapathi, MK Ganapathi, R
Citation: M. Aoyama et al., Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependentenzymes, BIOCH PHARM, 61(1), 2001, pp. 49-54
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: Clinical and biologic effects
Authors: Olencki, T Finke, J Tubbs, R Elson, P McLain, D Herzog, P Budd, GT Gunn, H Bukowski, RM
Citation: T. Olencki et al., Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: Clinical and biologic effects, J IMMUNOTH, 23(5), 2000, pp. 549-556
Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: A mechanism of immune escape
Authors: Rayman, P Uzzo, RG Kolenko, V Bloom, T Cathcart, MK Molto, L Novick, AC Bukowski, RM Hamilton, T Finke, JH
Citation: P. Rayman et al., Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: A mechanism of immune escape, CA J SCI AM, 6, 2000, pp. S81-S87
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer
Authors: Pelley, R Ganapathi, R Wood, L Rybicki, L McLain, D Budd, GT Peereboom, D Olencki, T Bukowski, RM
Citation: R. Pelley et al., A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer, CANC CHEMOT, 46(3), 2000, pp. 251-254
Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma
Authors: Bukowski, RM
Citation: Rm. Bukowski, Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma, SEMIN ONCOL, 27(2), 2000, pp. 204-212
Molecular mechanisms of immune dysfunction in renal cell carcinoma
Authors: Uzzo, RG Rayman, P Novick, AC Bukowski, RM Finke, JAH
Citation: Rg. Uzzo et al., Molecular mechanisms of immune dysfunction in renal cell carcinoma, CUR CLIN ON, 4, 2000, pp. 63-78
Adjuvant therapy of renal cell carcinoma
Authors: Bukowski, RM
Citation: Rm. Bukowski, Adjuvant therapy of renal cell carcinoma, CUR CLIN ON, 4, 2000, pp. 203-212
Interleukin-2 in metastatic renal cell carcinoma
Authors: Olencki, T Bukowski, RM
Citation: T. Olencki et Rm. Bukowski, Interleukin-2 in metastatic renal cell carcinoma, CUR CLIN ON, 4, 2000, pp. 301-318
Alterations in NF kappa B activation in T lymphocytes of patients with renal cell carcinoma
Authors: Uzzo, RG Clark, PE Rayman, P Bloom, T Rybicki, L Novick, AC Bukowski, RM Finke, JH
Citation: Rg. Uzzo et al., Alterations in NF kappa B activation in T lymphocytes of patients with renal cell carcinoma, J NAT CANC, 91(8), 1999, pp. 718-721
Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion in response to interleukin-12
Authors: Ulchaker, J Panuto, J Rayman, P Novick, A Elson, P Tubbs, R Finke, JH Bukowski, RM
Citation: J. Ulchaker et al., Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion in response to interleukin-12, J IMMUNOTH, 22(1), 1999, pp. 71-79
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma
Authors: Bukowski, RM Rayman, P Molto, L Tannenbaum, CS Olencki, T Peereboom, D Tubbs, R McLain, D Budd, GT Griffin, T Novick, A Hamilton, TA Finke, J
Citation: Rm. Bukowski et al., Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma, CLIN CANC R, 5(10), 1999, pp. 2780-2789
Immunotherapy in renal cell carcinoma
Authors: Bukowski, RM
Citation: Rm. Bukowski, Immunotherapy in renal cell carcinoma, ONCOLOGY-NY, 13(6), 1999, pp. 801
Chemoimmunotherapy of metastatic renal cell carcinoma
Authors: Bukowski, RM
Citation: Rm. Bukowski, Chemoimmunotherapy of metastatic renal cell carcinoma, CANCER INV, 17(6), 1999, pp. 460-461
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
Authors: Figlin, RA Thompson, JA Bukowski, RM Vogelzang, NJ Novick, AC Lange, P Steinberg, GD Belldegrun, AS
Citation: Ra. Figlin et al., Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma, J CL ONCOL, 17(8), 1999, pp. 2521-2529
Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine
Authors: Budd, GT Ganapathi, R Wood, L Snyder, J McLain, D Bukowski, RM
Citation: Gt. Budd et al., Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine, SEMIN ONCOL, 26(2), 1999, pp. 41-50
T-cell adoptive immunotherapy of metastatic renal cell carcinoma
Authors: Plautz, GE Bukowski, RM Novick, AC Klein, EA Kursh, ED Olencki, TE Yetman, RJ Pienkny, A Sandstrom, K Shu, SY
Citation: Ge. Plautz et al., T-cell adoptive immunotherapy of metastatic renal cell carcinoma, UROLOGY, 54(4), 1999, pp. 617-623
Altered drug interaction and regulation of topoisomerase II beta: Potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide
Authors: Grabowski, DR Holmes, KA Aoyama, M Ye, Y Rybicki, LA Bukowski, RM Ganapathi, MK Hickson, ID Ganapathi, R
Citation: Dr. Grabowski et al., Altered drug interaction and regulation of topoisomerase II beta: Potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide, MOLEC PHARM, 56(6), 1999, pp. 1340-1345
Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells
Authors: Uzzo, RG Rayman, P Kolenko, V Clark, PE Cathcart, MK Bloom, T Novick, AC Bukowski, RM Hamilton, T Finke, JH
Citation: Rg. Uzzo et al., Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells, J CLIN INV, 104(6), 1999, pp. 769-776
Therapeutic use of recombinant proteins
Authors: Bukowski, RM
Citation: Rm. Bukowski, Therapeutic use of recombinant proteins, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, 1999, pp. 393-427
Attenuation of drug-stimulated topoisomerase II DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium bufferis correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase II alpha
Authors: Aoyama, M Grabowski, DR Dubyak, GR Constantinou, AI Rybicki, LA Bukowski, RM Ganapathi, MK Hickson, ID Ganapathi, R
Citation: M. Aoyama et al., Attenuation of drug-stimulated topoisomerase II DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium bufferis correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase II alpha, BIOCHEM J, 336, 1998, pp. 727-733
Risultati: 1-25 |